| Drug General Information |
| Drug ID |
D01WQQ
|
| Former ID |
DIB005757
|
| Drug Name |
ABT-981
|
| Drug Type |
Monoclonal antibody
|
| Indication |
Osteoarthritis [ICD9: 715; ICD10:M15-M19, M47]
|
Phase 2 |
[1],
[2]
|
|---|
| Company |
AbbVie
|
| Target and Pathway |
| Target(s) |
Interleukin-1 alpha ligand |
Target Info |
Modulator |
[3]
|
|---|
| Interleukin-1 beta |
Target Info |
Modulator |
[3]
|
|
KEGG Pathway
|
MAPK signaling pathway
|
|
Cytokine-cytokine receptor interaction
|
|
Apoptosis
|
|
Osteoclast differentiation
|
|
Hematopoietic cell lineage
|
|
Non-alcoholic fatty liver disease (NAFLD)
|
|
Type I diabetes mellitus
|
|
Prion diseases
|
|
Salmonella infection
|
|
Pertussis
|
|
Leishmaniasis
|
|
Tuberculosis
|
|
Measles
|
|
Influenza A
|
|
Inflammatory bowel disease (IBD)
|
|
Rheumatoid arthritis
|
|
Graft-versus-host diseasehsa04010:MAPK signaling pathway
|
|
NF-kappa B signaling pathway
|
|
Toll-like receptor signaling pathway
|
|
NOD-like receptor signaling pathway
|
|
Cytosolic DNA-sensing pathway
|
|
TNF signaling pathway
|
|
Inflammatory mediator regulation of TRP channels
|
|
Alzheimer's disease
|
|
Legionellosis
|
|
Chagas disease (American trypanosomiasis)
|
|
African trypanosomiasis
|
|
Malaria
|
|
Amoebiasis
|
|
Herpes simplex infection
|
|
Graft-versus-host disease
|
|
NetPath Pathway
|
IL5 Signaling Pathway
|
|
IL1 Signaling Pathway
|
|
TCR Signaling PathwayNetPath_22:Leptin Signaling Pathway
|
|
IL2 Signaling Pathway
|
|
IL3 Signaling Pathway
|
|
TGF_beta_Receptor Signaling Pathway
|
|
Wnt Signaling Pathway
|
|
TCR Signaling Pathway
|
|
TNFalpha Signaling Pathway
|
|
PANTHER Pathway
|
Interleukin signaling pathway
|
|
Pathway Interaction Database
|
IL1-mediated signaling events
|
|
Validated transcriptional targets of deltaNp63 isoforms
|
|
a6b1 and a6b4 Integrin signalingil27pathway:IL27-mediated signaling events
|
|
IL12-mediated signaling events
|
|
IFN-gamma pathway
|
|
IL23-mediated signaling events
|
|
Cellular roles of Anthrax toxin
|
|
Reactome
|
Senescence-Associated Secretory Phenotype (SASP)
|
|
Interleukin-1 signaling
|
|
Interleukin-1 processingR-HSA-446652:Interleukin-1 signaling
|
|
Interleukin-1 processing
|
|
CLEC7A/inflammasome pathway
|
|
WikiPathways
|
SIDS Susceptibility Pathways
|
|
TCR Signaling Pathway
|
|
Senescence and Autophagy in Cancer
|
|
Cytokines and Inflammatory Response
|
|
Hypertrophy Model
|
|
MAPK Signaling Pathway
|
|
FAS pathway and Stress induction of HSP regulation
|
|
Hematopoietic Stem Cell Differentiation
|
|
Structural Pathway of Interleukin 1 (IL-1)
|
|
Spinal Cord Injury
|
|
Allograft Rejection
|
|
IL-1 signaling pathway
|
|
Interleukin-1 signalingWP75:Toll-like receptor signaling pathway
|
|
Monoamine Transport
|
|
Type II interferon signaling (IFNG)
|
|
Myometrial Relaxation and Contraction Pathways
|
|
Aryl Hydrocarbon Receptor Pathway
|
|
IL1 and megakaryotyces in obesity
|
|
Alzheimers Disease
|
|
Leptin signaling pathway
|
|
Interleukin-1 signaling
|
|
Folate Metabolism
|
|
Vitamin B12 Metabolism
|
|
Selenium Micronutrient Network
|
|
Serotonin Transporter Activity
|
|
Regulation of toll-like receptor signaling pathway
|
|
NOD pathway
|
| References |
| REF 1 | ClinicalTrials.gov (NCT02087904) A Phase 2a Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee Osteoarthritis |
|---|
| REF 2 | ClinicalTrials.gov (NCT02384538) A Phase 2a Study Evaluating the Safety and Efficacy of ABT-981 in Patients With Erosive Hand Osteoarthritis |
|---|
| REF 3 | Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig(TM)) molecule that specifically and potently neutralizes both IL-1alpha and IL-1beta. MAbs. 2015;7(3):605-19. |
|---|
